Vital Signs with Jacob Effron and Nikhil Krishnan Ep 52: knownwell CMO Dr. Angela Fitch on The Future of GLP-1s and New Approaches to Obesity Medicine
23 snips
Nov 14, 2024 Dr. Angela Fitch, Founder and CMO of knownwell, shares her expertise on obesity medicine, emphasizing the need for innovative care. She discusses the transformative potential of GLP-1 medications, highlighting their impact beyond obesity treatment to conditions like Alzheimer’s. The conversation also addresses challenges in insurance coverage and the importance of continuous and integrated care. Dr. Fitch advocates for recognizing obesity as a serious medical condition and stresses the necessity of creating a supportive environment for effective treatment.
AI Snips
Chapters
Transcript
Episode notes
Evolving Standards of Care
- The standard of care for obesity medicine is still being defined, highlighting the field's evolving nature.
- This lack of established standards contributes to fragmented and uncoordinated care.
KnownWell's Holistic Approach
- KnownWell aims to provide comprehensive, weight-inclusive care within a single ecosystem.
- This approach addresses the stigma and fragmented care often experienced by patients with obesity.
GLP-1 Research: The Unknowns
- GLP-1 research is ongoing, with much still unknown about the drugs' long-term effects.
- Novo Nordisk's early investment in GLP-1s was crucial due to limited funding and research elsewhere.